NCT07384377尚未招募3 期
A Phase III Trial to Evaluate the Efficacy and Safety of JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
Shanghai JMT-Bio Inc.0 个研究点目标入组 123 人开始时间: 2026年2月6日最近更新:
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 123
- 主要终点
- Progressive Free Survive (PFS) assessed by Independent Review Committee
研究概览
简要总结
The study is being conducted to evaluate the efficacy and safety of JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age≥18 years old.
- •Unresectable locally advanced or distant metastatic BRAFV600E wild-type colorectal cancer diagnosed histologically or cytologically.
- •After treatment with oxaliplatin, 5-fluorouracil (such as 5-FU, Capecitabine) , irinotecan (DMMR/MSI-H subjects also need anti-PD-1/PD-L1 antibody treatment failure).
- •HER2-positive (defined as IHC3+ or IHC 2+/FISH +).
- •According to the response evaluation criteria for solid tumors (RECIST 1.1), having at least one assessable lesion, assessable lesions should not have received local treatment such as radiotherapy (lesions located within the previously treated area may also be targeted if progression is confirmed).
- •ECOG PS of 0-
- •Expected survival ≥ 3 months.
- •Participants with adequate organ functions.
- •Female and male patients of childbearing age agree to take adequate contraceptive measures during and upon completion of the study for 7 months after the last dose. Female participants of childbearing age must have a negative blood pregnancy test within 7 days before the first dose or randomization.
- •Voluntarily agree to participate in the study and sign the informed consent.
排除标准
- •Participants who have previously been treated with an anti-HER2 ADC loaded with topoisomerase I inhibitors.
- •Participants with brain metastasis or spinal cord compression at screening.
- •Previous antineoplastic therapy toxicities did not revert to a CTCAE v5.0 grade rating of ≤
- •There are obvious clinical manifestations of gastrointestinal abnormalities, including but not limited to: having experienced intestinal obstruction or symptoms and signs of intestinal obstruction within 3 months prior to administration; having had gastrointestinal perforation, gastrointestinal fistula, or intra-abdominal abscess within 3 months prior to administration; having experienced gastrointestinal bleeding of CTCAE grade ≥ 3 within 3 months prior to administration, or having had gastrointestinal bleeding within the previous 1 month.
- •Participants who have undergone major surgery or had invasive intervention within 28 days before the randomization. Or those who plan to undergo systematic or local tumor resection during the trial.
- •Participate in another clinical trial, unless it is an observational (non-intervention) clinical trial or is in the follow-up period of an intervention trial.
- •Participants who have used any Chinese herbal medicine or Chinese patent medicine approved by the national drug regulatory authority for its anti-cancer properties within the previous 14 days (regardless of the type of cancer); have received palliative radiotherapy within the 14 days prior to randomization; have received systemic anti-tumor treatment within 4 weeks or 5 half-life (whichever is shorter but at least 2 weeks) prior to randomization.
- •Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product.
- •Participants who have active bacterial, fungal or viral infections 14 days before the randomization.
- •Within the 14 days before the randomization, participants who had a situation where there was an uncontrollable need for frequent drainage or medical intervention in the serous cavity effusion.
- •Participant with positive hepatitis B surface antigen (HBsAg) and HBV-DNA is higher than 500 IU/mL (or 2500 copies/ml) (whichever is lower) ; Participants with positive for hepatitis C (HCV) antibody and HCV-RNA is higher than 1000 copies/ml or UNL (whichever is lower).
- •Has activity or a history of interstitial lung disease at any stage and/or pulmonary function injury, a history of interstitial pneumonia requiring hormone therapy, or the imaging cannot rule out suspected interstitial lung disease/pneumonia at screening.
- •Has a history of severe cardiovascular disease.
- •History of any other malignant tumors within 5 years.
- •Pregnant or breastfeeding women.
- •Otherwise considered inappropriate for the study by the investigator.
研究组 & 干预措施
Physician choiced treatment
Active Comparator
干预措施: Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib. (Drug)
JSKN003
Active Comparator
干预措施: JSKN003 (Drug)
结局指标
主要结局
Progressive Free Survive (PFS) assessed by Independent Review Committee
时间窗: Every 6 weeks, up to 3 years
次要结局
- Progressive Free Survive (PFS) assessed by the Investigator(Every 6 weeks, up to 3 years)
- Objective response rate (ORR) assessed by the Investigator or IRC(Every 6 weeks, up to 3 years)
- Duration of Response (DOR) assessed by the Investigator or IRC(Every 6 weeks, up to 3 years)
- Overall Survival (OS)(Up to approximately 3 years)
- Incidence and severity of TEAE and SAE(Up to approximately 3 years)
- Blood concentration of JSKN003(Up to approximately 3 years)
- Blood concentration of total antibodies for JSKN003(Up to approximately 3 years)
- Blood concentration of free toxins for JSKN003(Up to approximately 3 years)
- Anti-drug antibodies (ADA) related to JSKN003(Up to approximately 3 years)
研究者
相似试验
招募中
1 期
JSKN022 in Subjects With Advanced Malignant Solid TumorsNCT07292402Jiangsu Alphamab Biopharmaceuticals Co., Ltd225
尚未招募
2 期
This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax MalariaMalariaNCT07430592R. Kiplin Guy104
招募中
2 期
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT07266441Janssen Research & Development, LLC157
招募中
1 期
SKB105 for Injection in Advanced Solid TumorsNCT07380386Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.256
尚未招募
4 期
Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic CancerNCT07302841Tianjin Medical University Cancer Institute and Hospital28